OMNIAB INC · Data as of 2026-09-08
H2 2026
They expect to provide further updates on the potentially registrational IMVT-1402 difficult-to-treat rheumatoid arthritis program and report topline data from the proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus in the second half of calendar year 2026.Source filing
H2 2026
Topline results of the Phase 2a trial evaluating TEV-'408 for celiac disease continue to be expected in the second half of 2026 .Source filing
2027
In calendar year 2027, topline data are anticipated for the potentially registrational trials evaluating IMVT-1402 in Graves' disease and myasthenia gravis.Source filing
2028
Topline data are expected to follow in calendar year 2028 for the potentially registrational trials of IMVT-1402 in chronic inflammatory demyelinating polyneuropathy and Sjögren's disease.Source filing